Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (151-160 of 247) with videos related to

Pageof 25
Sort By:
Viruses|September 28, 2021
Monitoring Natural SARS-CoV-2 Infection in Lions (<i>Panthera leo</i>) at the Barcelona Zoo: Viral Dynamics and Host ResponsesHugo Fernández-Bellon, Jordi Rodon, Leira Fernández-Bastit, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Advances in Therapy|July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II TrialRenata Ferrarotto, Luana G Sousa, Yun Qing, et al.
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Cancer Discovery|February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsTimothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancerRongjie Fu, Yalong Wang, Ishita Rehman, et al.
Pageof 25

Showing results (151-160 of 247) with videos related to

Sort By:
Pageof 25
Viruses|September 28, 2021
Monitoring Natural SARS-CoV-2 Infection in Lions (<i>Panthera leo</i>) at the Barcelona Zoo: Viral Dynamics and Host ResponsesHugo Fernández-Bellon, Jordi Rodon, Leira Fernández-Bastit, et al.
Journal for Immunotherapy of Cancer|September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinomaMouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Advances in Therapy|July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II TrialRenata Ferrarotto, Luana G Sousa, Yun Qing, et al.
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Cancer Discovery|February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsTimothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancerRongjie Fu, Yalong Wang, Ishita Rehman, et al.
Pageof 25